Moreover, it was previously reported that bromhexine, an FDA-approved ingredient in mucolytic cough suppressants, had the capacity to inhibit TMPRSS2 activity and to reduce prostate cancer enlargement and metastases [188]. This evidence concerns the gene TMPRSS2 and Familial prostate cancer.